At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 168 enrolled / 168 target
Drug / intervention
CAR-Tbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Safety and Efficacy of Chimeric Antigen Receptor T Cell (CAR-T) Treating Relaspe/Refractory CD19/CD20/CD22/CD30 Postive Non-Hodgkin Lymphoma
The First Affiliated Hospital of Soochow University·interventional·Posted Jun 23, 2017·Updated Jun 3, 2026
In Brief
A Phase 2 clinical trial evaluating CAR-T for Relapsed Non Hodgkin Lymphoma and 2 related conditions. Completed, enrolled 168 participants across 1 site.
Signals
Enrolling ahead of pace
Detailed Summary
This study is a single arm study to investigate the efficacy and safety of CAR-T targeted CD19/CD20/CD22/CD30 in relapse and refractory non-Hodgkin lymphoma patients. Ten patients will recruieted, admitted in hospital for 1 month for the CAR-T treatment and follow-up for at least 2 years.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRelapsed Non Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, CAR - T CD19/CD20/CD22/CD30
CountriesChina
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
Enrollment StartJun 2017
First PostedJun 2017
Primary CompletionJan 2024
TodayJul 2026
First PostedJun 23, 2017
Enrollment StartJun 1, 2017
Primary CompletionJan 31, 2024
TodayJul 2, 2026
Enrollment to primary: 6.7 yearsPosted 9.0 years ago
Arms & Interventions
Treatment groupexperimental
the group of patients who received CAR-T treatment
Biological: CAR-T
Interventions
CAR-Tbiological
For eligible patients, CAR-T cells targeted to patients' tumor cell antigen will be infused after 48 hours later of chemotherapy